Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Ceftazidime (1000mg) + Tobramycin (120mg) Injection
Therapeutic Category
Antibacterials, Antibiotic
Dosage Form
Injection
Packaging Type
Vial + Water
Packaging
1.120gm
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Dimezeft TZ 1120 Injection containing Ceftazidime and Tobramycin is used for the management of severe and complicated bacterial infections. It provides broad-spectrum antibacterial coverage and supports effective infection control.
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis, while Tobramycin is an aminoglycoside antibiotic that interferes with bacterial protein synthesis, enhancing overall antibacterial action.
The injection is widely used in hospital and critical care settings for serious infections such as respiratory tract infections, urinary tract infections, intra-abdominal infections, and sepsis, leading to consistent institutional demand.
With rising incidence of resistant and severe bacterial infections, this product offers strong business potential for retailers and distributors. Its dual antibiotic synergy, broad clinical relevance, and steady market demand make it a reliable product for growth in the critical care antibiotic segment.
Some patients may experience injection site pain, nausea, diarrhea, rash, dizziness, or headache. Rarely, kidney toxicity, hearing disturbances (ototoxicity), or severe allergic reactions may occur and require immediate medical attention.
Dimezeft TZ 1120 Injection is indicated for severe respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, septicemia, hospital-acquired infections, and other serious bacterial infections caused by susceptible organisms. It helps eliminate resistant bacteria and improves clinical outcomes in critical conditions.
This injection should be administered strictly under medical supervision by qualified healthcare professionals. Renal function monitoring is recommended during therapy, especially in prolonged use. Complete the prescribed course to prevent resistance.
Store below 25°C, protected from moisture and direct sunlight. Keep the vial in its original packaging and out of reach of children.
Composition : Amoxycillin (250mg)
Composition : Amoxycillin I.P. 250mg + 1.66 Millions Lactic Acid Bacillus
Composition : Amoxycillin (500mg)
Composition : Amoxycillin (500mg) + Lactic Acid Bacillus (1.66 Millions)
Composition : Amoxycillin Trihydrate I.P. 250mg + Cloxacillin I.P. 250mg + Lactic Acid Bacillus 1.7 Billion Spores
Composition : Amoxycillin (1000mg) + Clavulanic Acid (200mg)
Composition : Amoxycillin (125mg) + Clavulanic Acid (25mg)
Composition : Amoxycillin (250mg) + Clavulanic Acid (50mg)
Composition : Amoxycillin (500mg) + Clavulanic Acid (100mg)
Composition : Amoxycillin (500mg) + Clavulanic Acid (125mg) + Lactobacillus
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Ceftazidime 1000mg + Tobramycin 120mg Injection has strong demand in the hospital and critical care antibiotic segment, making it a high-value product for medical distributors, wholesalers, and pharma franchise partners looking to expand in the PCD pharma franchise market.
Medical distributors and wholesalers can benefit from the consistent demand for this formulation in severe and resistant bacterial infections, including respiratory tract infections, hospital-acquired infections, septicemia, urinary tract infections, and complicated infections. It strengthens their injectable antibiotic portfolio.
Yes, Cafoli Lifecare offers PCD pharma franchise opportunities for Ceftazidime 1000mg + Tobramycin 120mg Injection with monopoly rights, promotional support, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from strong hospital demand, attractive institutional sales opportunities, good margins, timely availability, and professional marketing support when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this injectable antibiotic combination can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, bulk procurement, pricing details, and distribution support services.